Skip to main content
Erschienen in: Neurotherapeutics 2/2015

01.04.2015 | Original Article

Diffusion Efficiency and Bioavailability of Resveratrol Administered to Rat Brain by Different Routes: Therapeutic Implications

verfasst von: Xiao-Hong Shu, Li-Li Wang, Hong Li, Xue Song, Shun Shi, Jia-Yao Gu, Mo-Li Wu, Xiao-Yan Chen, Qing-You Kong, Jia Liu

Erschienen in: Neurotherapeutics | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Resveratrol possesses anti-tumor activities against central nervous system (CNS) tumors in vitro but has not yet been used clinically due to its low bioavailability, particularly in the CNS. This study thus aimed to elucidate brain bioavailability of trans-resveratrol by monitoring brain concentrations and dwell times following administration of resveratrol through intragastric, intraperitoneal, external carotid artery/ECA and intrathecal routes. In parallel, we evaluated the biological responses of rat RG2 glioblastoma cells as well as RG2-formed rat intracranial glioblastomas treated with resveratrol via intrathecal administration. The results revealed that resveratrol was detected in rat brains except when administered systemically. Intrathecal administration of reseveratrol led to abundant apoptotic foci and increased staining of the autophagy proteins, LC-3 and Beclin-1 and shrinkage of the intracranial tumors. In conclusion, the BBB penetrability of resveratrol is remarkably increased by intracthecal administration. Regular short-term resveratrol treatments suppress growth and enhance autophagic and apoptotic activities of rat RG2 glioblastoma cells in vitro and in vivo. Therefore, intrathecal administration of resveratrol could be an optimal intervention approach in the adjuvant management of brain malignancies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275:218–20.PubMedCrossRef Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275:218–20.PubMedCrossRef
2.
Zurück zum Zitat Mancuso R, del Valle J, Modol L, Martinez A, Granado-Serrano AB, Ramirez-Núñez O, et al. Resveratrol improves motoneuron function and extends survival in SOD1 (G93A) ALS mice. Neurotherapeutics 2014;11:419–32.PubMedCentralPubMed Mancuso R, del Valle J, Modol L, Martinez A, Granado-Serrano AB, Ramirez-Núñez O, et al. Resveratrol improves motoneuron function and extends survival in SOD1 (G93A) ALS mice. Neurotherapeutics 2014;11:419–32.PubMedCentralPubMed
3.
Zurück zum Zitat Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337–42.PubMedCrossRef Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337–42.PubMedCrossRef
4.
Zurück zum Zitat Juan ME, Vinardell MP, Planas JM. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 2002; 132: 257–60.PubMed Juan ME, Vinardell MP, Planas JM. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 2002; 132: 257–60.PubMed
5.
Zurück zum Zitat Sangeetha MK, Vallabi DE, Sali VK, Thanka J, Vasanthi HR. Sub-acute toxicity profile of a modified resveratrol supplement. Food Chem Toxicol 2013;59:492–500.PubMedCrossRef Sangeetha MK, Vallabi DE, Sali VK, Thanka J, Vasanthi HR. Sub-acute toxicity profile of a modified resveratrol supplement. Food Chem Toxicol 2013;59:492–500.PubMedCrossRef
6.
Zurück zum Zitat Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, Sun GY, et al. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 2002; 958: 439–47.PubMedCrossRef Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, Sun GY, et al. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 2002; 958: 439–47.PubMedCrossRef
7.
Zurück zum Zitat Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of resveratrol. Ann N Y Acad Sci 2011; 1215: 161–9.PubMedCrossRef Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of resveratrol. Ann N Y Acad Sci 2011; 1215: 161–9.PubMedCrossRef
9.
Zurück zum Zitat Juan ME, Maijó M, Planas JM. Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J Pharm Biomed Anal 2010; 51: 391–8.PubMedCrossRef Juan ME, Maijó M, Planas JM. Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J Pharm Biomed Anal 2010; 51: 391–8.PubMedCrossRef
10.
Zurück zum Zitat Das S, Lin HS, Ho PC, Ng KY. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res 2008; 25:2593–600.PubMedCrossRef Das S, Lin HS, Ho PC, Ng KY. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res 2008; 25:2593–600.PubMedCrossRef
11.
Zurück zum Zitat Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 2010; 70: 9003–11.PubMedCentralPubMedCrossRef Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 2010; 70: 9003–11.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Burkhardt JK, Riina HA, Shin BJ, Moliterno JA, Hofstetter CP, Boockvar JA. Intra-arterial chemotherapy for malignant gliomas: a critical analysis. Interv Neuroradiol 2011; 17: 286–95.PubMedCentralPubMed Burkhardt JK, Riina HA, Shin BJ, Moliterno JA, Hofstetter CP, Boockvar JA. Intra-arterial chemotherapy for malignant gliomas: a critical analysis. Interv Neuroradiol 2011; 17: 286–95.PubMedCentralPubMed
13.
Zurück zum Zitat Figueiredo EG, Faria JW, Teixeira MJ. Treatment of recurrent glioblastoma with intra-arterial BCNU [1, 3-bis (2-chloroethyl)-1- nitrosourea]. Arq Neuropsiquiatr 2010; 68: 778–82.PubMedCrossRef Figueiredo EG, Faria JW, Teixeira MJ. Treatment of recurrent glioblastoma with intra-arterial BCNU [1, 3-bis (2-chloroethyl)-1- nitrosourea]. Arq Neuropsiquiatr 2010; 68: 778–82.PubMedCrossRef
14.
Zurück zum Zitat Guerin C, Olivi A, Weingart JD, Lawson HC, Brem H. Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest New Drugs 2004; 22: 27–37.PubMedCrossRef Guerin C, Olivi A, Weingart JD, Lawson HC, Brem H. Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest New Drugs 2004; 22: 27–37.PubMedCrossRef
15.
Zurück zum Zitat Seigers R, Schagen SB, Van Tellingen O, Dietrich J. Chemotherapy-related cognitive dysfunction: current animal studies and future directions. Brain Imaging Behav 2013; 7: 453–9.PubMedCrossRef Seigers R, Schagen SB, Van Tellingen O, Dietrich J. Chemotherapy-related cognitive dysfunction: current animal studies and future directions. Brain Imaging Behav 2013; 7: 453–9.PubMedCrossRef
16.
Zurück zum Zitat Liu HL, Hua MY, Chen PY, Chu PC, Pan CH, Yang HW, et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 2010; 255: 415–25.PubMedCrossRef Liu HL, Hua MY, Chen PY, Chu PC, Pan CH, Yang HW, et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 2010; 255: 415–25.PubMedCrossRef
17.
Zurück zum Zitat Shu XH, Li H, Sun XX, Wang Q, Sun Z, Wu ML, et al. Metabolic patterns and biotransformation activities of resveratrol in human glioblastoma cells: relevance with therapeutic efficacies. PLoS ONE 2011; 6: e27484.PubMedCentralPubMedCrossRef Shu XH, Li H, Sun XX, Wang Q, Sun Z, Wu ML, et al. Metabolic patterns and biotransformation activities of resveratrol in human glioblastoma cells: relevance with therapeutic efficacies. PLoS ONE 2011; 6: e27484.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Sun Z, Shi S, Li H, Shu XH, Chen XY, Kong QY, et al. Evaluation of resveratrol sensitivities and metabolic patterns in human and rat glioblastoma cells. Cancer Chemother Pharmacol 2013; 72: 965–73.PubMedCrossRef Sun Z, Shi S, Li H, Shu XH, Chen XY, Kong QY, et al. Evaluation of resveratrol sensitivities and metabolic patterns in human and rat glioblastoma cells. Cancer Chemother Pharmacol 2013; 72: 965–73.PubMedCrossRef
19.
Zurück zum Zitat Valable S, Lemasson B, Farion R, Beaumont M, Segebarth C, Remy C, et al. Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal in vivo and ex vivo study. NMR Biomed 2008;21:1043–56.PubMedCrossRef Valable S, Lemasson B, Farion R, Beaumont M, Segebarth C, Remy C, et al. Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal in vivo and ex vivo study. NMR Biomed 2008;21:1043–56.PubMedCrossRef
20.
Zurück zum Zitat Gu YT, Xue YX, Wang YF, Wang JH, Chen X, Shangguan QR, et al. Minoxidil sulfate induced the increase in blood-brain tumor barrier permeability through ROS/RhoA/PI3K/PKB signaling pathway. Neuropharmacology 2013;75:407–15.PubMedCrossRef Gu YT, Xue YX, Wang YF, Wang JH, Chen X, Shangguan QR, et al. Minoxidil sulfate induced the increase in blood-brain tumor barrier permeability through ROS/RhoA/PI3K/PKB signaling pathway. Neuropharmacology 2013;75:407–15.PubMedCrossRef
21.
Zurück zum Zitat Loch-Neckel G, Nemen D, Puhl AC, Fernandes D, Stimamiglio MA, Alvarez Silva M, et al. Stealth and non-stealth nanocapsules, containing camptothecin: in-vitro and in-vivo activity on B16-F10 melanoma. J Pharm Pharmacol 2007;59:1359–64.PubMedCrossRef Loch-Neckel G, Nemen D, Puhl AC, Fernandes D, Stimamiglio MA, Alvarez Silva M, et al. Stealth and non-stealth nanocapsules, containing camptothecin: in-vitro and in-vivo activity on B16-F10 melanoma. J Pharm Pharmacol 2007;59:1359–64.PubMedCrossRef
22.
Zurück zum Zitat Bock KW, Köhle C. UDP-glucuronosyltransferase 1A6: structural, functional, and regulatory aspects. Methods Enzymol 2005; 400: 57–75.PubMed Bock KW, Köhle C. UDP-glucuronosyltransferase 1A6: structural, functional, and regulatory aspects. Methods Enzymol 2005; 400: 57–75.PubMed
23.
Zurück zum Zitat Heydel JM, Holsztynska EJ, Legendre A, Thiebaud N, Artur Y, Le Bon AM. UDP-glucuronosyltransferases (UGTs) in neuro-olfactory tissues: expression, regulation, and function. Drug Metab Rev 2010; 42: 74–97.PubMedCrossRef Heydel JM, Holsztynska EJ, Legendre A, Thiebaud N, Artur Y, Le Bon AM. UDP-glucuronosyltransferases (UGTs) in neuro-olfactory tissues: expression, regulation, and function. Drug Metab Rev 2010; 42: 74–97.PubMedCrossRef
24.
Zurück zum Zitat Emlia Juan M, Buenafuente J, Casals I, Planas JM. Plasmatic levels of trans-resveratrol in rats. Food Res International 2002;35:195–9.CrossRef Emlia Juan M, Buenafuente J, Casals I, Planas JM. Plasmatic levels of trans-resveratrol in rats. Food Res International 2002;35:195–9.CrossRef
26.
Zurück zum Zitat Ates O, Cayli SR, Yucel N, Altinoz E, Kocak A, Durak MA, et al. Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J Clin Neurosci 2007;14:256–60.PubMedCrossRef Ates O, Cayli SR, Yucel N, Altinoz E, Kocak A, Durak MA, et al. Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J Clin Neurosci 2007;14:256–60.PubMedCrossRef
28.
Zurück zum Zitat Ates O, Cayli S, Altinoz E, Gurses I, Yucel N, Sener M, et al. Neuroprotection by resveratrol against traumatic brain injury in rats. Mol Cell Biochem 2007;294:137–44.PubMedCrossRef Ates O, Cayli S, Altinoz E, Gurses I, Yucel N, Sener M, et al. Neuroprotection by resveratrol against traumatic brain injury in rats. Mol Cell Biochem 2007;294:137–44.PubMedCrossRef
29.
Zurück zum Zitat Ganapathy S, Chen Q, Singh KP, Shankar S, Srivastava RK. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS ONE 2010;5:e15627.PubMedCentralPubMedCrossRef Ganapathy S, Chen Q, Singh KP, Shankar S, Srivastava RK. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS ONE 2010;5:e15627.PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat Roy P, Kalra N, Prasad S, George J, Shukla Y. Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways. Pharm Res 2009;26:211–7.PubMedCrossRef Roy P, Kalra N, Prasad S, George J, Shukla Y. Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways. Pharm Res 2009;26:211–7.PubMedCrossRef
31.
Zurück zum Zitat Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007;224:274–83.PubMedCentralPubMedCrossRef Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007;224:274–83.PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Sun Z, Li H, Shu XH, Shi H, Chen XY, Kong QY, et al. Distinct sulfonation activities in resveratrol-sensitive and resveratrol-insensitive human glioblastoma cells. FEBS J 2012;279:2381–92.PubMedCrossRef Sun Z, Li H, Shu XH, Shi H, Chen XY, Kong QY, et al. Distinct sulfonation activities in resveratrol-sensitive and resveratrol-insensitive human glioblastoma cells. FEBS J 2012;279:2381–92.PubMedCrossRef
33.
Zurück zum Zitat Tahara K, Miyazaki Y, Kawashima Y, Kreuter J, Yamamoto H. Brain targeting with surface-modified poly (D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration. Eur J Pharm Biopharm 2011;77:84–8.PubMedCrossRef Tahara K, Miyazaki Y, Kawashima Y, Kreuter J, Yamamoto H. Brain targeting with surface-modified poly (D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration. Eur J Pharm Biopharm 2011;77:84–8.PubMedCrossRef
34.
Zurück zum Zitat De la Calle JL, Paíno CL. A procedure for direct lumbar puncture in rats. Brain Res Bull 2002;59:245–50.PubMedCrossRef De la Calle JL, Paíno CL. A procedure for direct lumbar puncture in rats. Brain Res Bull 2002;59:245–50.PubMedCrossRef
35.
Zurück zum Zitat Bullard DE, Bigner SH, Bigner DD. Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model. Cancer Res 1985;45:5240–45.PubMed Bullard DE, Bigner SH, Bigner DD. Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model. Cancer Res 1985;45:5240–45.PubMed
36.
Zurück zum Zitat Wright BL, Lai JT, Sinclair AJ. Cerebrospinal fluid and lumbar puncture: a practical review. J Neurol 2012;259:1530–45.PubMedCrossRef Wright BL, Lai JT, Sinclair AJ. Cerebrospinal fluid and lumbar puncture: a practical review. J Neurol 2012;259:1530–45.PubMedCrossRef
37.
Zurück zum Zitat Lavi R, Rowe JM, Avivi I. Lumbar puncture: it is time to change the needle. Eur Neurol 2010;64:108–13.PubMedCrossRef Lavi R, Rowe JM, Avivi I. Lumbar puncture: it is time to change the needle. Eur Neurol 2010;64:108–13.PubMedCrossRef
38.
Zurück zum Zitat Zhang F, Shi JS, Zhou H, Wilson B, Hong JS, Gao HM. Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol Pharmacol 2010;78:466–77.PubMedCentralPubMedCrossRef Zhang F, Shi JS, Zhou H, Wilson B, Hong JS, Gao HM. Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol Pharmacol 2010;78:466–77.PubMedCentralPubMedCrossRef
39.
Zurück zum Zitat Fukui M, Choi HJ, Zhu BT. Mechanism for the protective effect of resveratrol against oxidative stress-induced neuronal death. Free Radic Biol Med 2010;49:800–13.PubMedCentralPubMedCrossRef Fukui M, Choi HJ, Zhu BT. Mechanism for the protective effect of resveratrol against oxidative stress-induced neuronal death. Free Radic Biol Med 2010;49:800–13.PubMedCentralPubMedCrossRef
41.
Zurück zum Zitat Ceaglio N, Orozco G, Etcheverrigaray M, Mattio M, Kratje R, Perotti N, et al. High performance collection of cerebrospinal fluid in rats: evaluation of erythropoietin penetration after osmotic opening of the blood-brain barrier. J Neurosci Methods 2013;219:70–5.PubMedCrossRef Ceaglio N, Orozco G, Etcheverrigaray M, Mattio M, Kratje R, Perotti N, et al. High performance collection of cerebrospinal fluid in rats: evaluation of erythropoietin penetration after osmotic opening of the blood-brain barrier. J Neurosci Methods 2013;219:70–5.PubMedCrossRef
42.
Zurück zum Zitat Mothe AJ, Bozkurt G, Catapano J, Zabojova J, Wang X, Keating A, et al. Intrathecal transplantation of stem cells by lumbar puncture for thoracic spinal cord injury in the rat. Spinal Cord 2011;49:967–73.PubMedCrossRef Mothe AJ, Bozkurt G, Catapano J, Zabojova J, Wang X, Keating A, et al. Intrathecal transplantation of stem cells by lumbar puncture for thoracic spinal cord injury in the rat. Spinal Cord 2011;49:967–73.PubMedCrossRef
Metadaten
Titel
Diffusion Efficiency and Bioavailability of Resveratrol Administered to Rat Brain by Different Routes: Therapeutic Implications
verfasst von
Xiao-Hong Shu
Li-Li Wang
Hong Li
Xue Song
Shun Shi
Jia-Yao Gu
Mo-Li Wu
Xiao-Yan Chen
Qing-You Kong
Jia Liu
Publikationsdatum
01.04.2015
Verlag
Springer US
Erschienen in
Neurotherapeutics / Ausgabe 2/2015
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-014-0334-6

Weitere Artikel der Ausgabe 2/2015

Neurotherapeutics 2/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.